Bing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).
Bing Xia, MD
Advertisement
Articles by Bing Xia, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5